CA-ROOTSTOCK-SOFTWARE
30.6.2020 07:02:07 CEST | Business Wire | Press release
Some partnerships are strengthened through difficult times. Rootstock Software and Mobidiag Ltd . found themselves in just this situation. Collaborating since 2018, the two companies have now been working toward respective missions around the COVID-19 pandemic. Mobidiag is a manufacturer of molecular diagnostic solutions for the detection of infectious diseases. Rootstock is a leading provider of Cloud ERP on the Salesforce Platform .
When the pandemic hit, Mobidiag quickly mobilized to develop and launch tests to detect COVID-19 infections. In April 2020, it was granted emergency use authorization for its COVID-19 diagnostic tests in Finland, Sweden and France. Now, in June, it has received CE-IVD markings for its two tests that enable rapid and reliable detection of COVID-19 infections:
- Novodiag™ COVID-19 for single, on-demand tests.
- Amplidiag™ COVID-19 for batch volume tests at large laboratories.
These two tests are complemented by an antibody test, Anti-SARS-CoV-2 Rapid Test , which Mobidiag distributes from its venture partner in China, Autobio Diagnostics.
All together these tests mean Mobidiag offers a comprehensive diagnostic solution for novel coronavirus infections for hospital and lab-based settings, and it comes at an opportune time, as the demand for COVID-19 diagnostic devices and tests is high around the world.
“Since April 2018, we have used Rootstock ERP along with Salesforce Sales Cloud and Service Cloud,” said Harri Vaihinen, Senior Business Solution Specialist at Mobidiag . “We worked with Rootstock to enable greater integration and automation of our key processes across sales, inventory and service for greater efficiency, synchronization and a full view of data across these departments. Since we had this ERP and integrated processes in place, we were able to use these tools to support our rapidly increasing sales, including COVID-19 tests.”
“During the pandemic, Rootstock’s mission has been to support manufacturers, distributors and supply chain organizations in continuing to deliver vital products around the world,” said Pat Garrehy , CEO of Rootstock Software . “It’s impressive to have seen the strides Mobidiag has made to get their COVID-19 tests to market in such an accelerated timeframe. The world needs COVID-19 testing, and it’s gratifying to play even a small role in supporting Mobidiag in their objective to detect COVID-19 infections and slow the spread of the virus.”
Salesforce, Sales Cloud and others are among the trademarks of salesforce.com, inc.
About Mobidiag
Mobidiag is a commercial stage, fast growing molecular diagnostics company whose fast, cost-effective, widely applicable and robust technology makes the power of molecular diagnostics available to address the spread of infectious diseases and antimicrobial resistance by rapid detection of pathogens and their potential resistance to antibiotics. Through its Amplidiag™ and Novodiag™ solutions, Mobidiag offers a comprehensive range of molecular diagnostic solutions for the detection of infectious diseases to laboratories of all sizes.
About Rootstock
Rootstock Software is a worldwide provider of cloud ERP designed for manufacturing, distribution, and supply chain organizations. Rootstock Cloud ERP is a flexible, modern, and digitally connected system that transforms companies to deliver a more personalized customer experience, efficiently scale operations, and out-service the competition.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200629005024/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Textron Aviation Marks 500th Cessna Citation Latitude Rollout22.9.2026 16:19:00 CEST | Press release
Milestone reinforces the Citation Latitude’s position as the world’s best-selling midsize business jet. Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company, today announced the rollout of the 500th Cessna Citation Latitude business jet from the company’s Wichita, Kansas, manufacturing facility. The production milestone highlights the continued success of the world’s best-selling midsize business jet and recognizes the employees whose craftsmanship and dedication have helped make the Citation Latitude the trusted choice for operators around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260922867287/en/ Textron Aviation marks 500th Cessna Citation Latitude rollout. (Photo Credit: Textron Aviation) “The rollout of the 500th Citation Latitude is a testament to the employees who build this aircraft with dedication and pride every day,” said Eric Cardinali, senior vice president, Manufacturing. “Behind every aircr
OCP Announces Date of Second Quarter and First Half 2026 Earnings22.9.2026 16:00:00 CEST | Press release
OCP S.A. (“OCP” or the “Company”), a global leader in the fertilizer industry, will release its second quarter and first half 2026 results on Tuesday, September 29, 2026. The results will be available to holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers on the OCP Intralinks portal from 10:00 a.m. EDT, 2:00 p.m. Morocco (GMT) and 3:00 p.m. London time (GMT+1). OCP senior management will host a conference call to discuss second quarter and first half 2026 results at 11:00 a.m. EDT, 3:00 p.m. Morocco (GMT) and 4:00 p.m. London time (GMT+1) on Tuesday, September 29, 2026, for holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers. Eligible parties that have not already registered for access to the Intralinks portal may do so by contacting the Investor Relations Department by emailing g.laraki@ocpgroup.ma. About OCP OCP is a global leader in the fertilizer industry, backed by almost a century
Quaise Energy Selected for Up to $25 Million in U.S. Department of Energy Support to Advance World's First Commercial Superhot Geothermal Power Plant22.9.2026 15:30:00 CEST | Press release
Quaise's Project Obsidian, a commercial-scale superhot Enhanced Geothermal System (EGS), selected to receive federal funding as part of $99 million DOE effort to advance geothermal energy development across the United States Supports completion of the first well triplet at Project Obsidian, targeting more than 25 megawatts of gross electric power Project team includes Pacific Northwest National Laboratory, Lawrence Berkeley National Laboratory and Oregon State University Quaise Energy, a leading developer of utility-scale superhot geothermal energy, today announced that it has been selected by the U.S. Department of Energy (DOE) for up to $25 million in funding under the Next-Generation Geothermal Field Tests and Geothermal Resource Characterization and Confirmation funding opportunity. The support brings the U.S. closer to commercializing superhot Enhanced Geothermal Systems — technology that could unlock firm, clean power from hot rock beneath virtually any geography in the country.
Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 202622.9.2026 15:30:00 CEST | Press release
Late-Breaking Abstract to Feature New Data from First Phase 3 Registrational Study of Arcotatug Tavatecan in Previously Treated Advanced Gastric CancerTAK-928 Presentations Reinforce Potential in Patients with Immunotherapy-Resistant Non-Small Cell Lung Cancer (NSCLC) and Previously Untreated NSCLCTakeda Continues to Progress Clinical Development of Arcotatug Tavatecan and TAK-928; New Non-Squamous NSCLC Sub-Trial Added to Global Phase 3 MarsLight-11 Study Evaluating TAK-928 vs. Docetaxel Monotherapy Takeda(TSE:4502/NYSE:TAK)announced that new data from its oncology pipeline and portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress, taking place October 23-27, 2026, in Madrid, Spain. Key data will include a late-breaking abstract on arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343*) and two presentations on TAK-928 (Innovent R&D code: IBI363*). Clinical and real-world analyses of ALUNBRIG® (brigatinib) and FRUZAQLA® (fruquintinib) will also be
From CSR to Public Health Impact: How Colgate Bright Smiles, Bright Futures® is Driving Behavior Change for the Next Billion Children and Their Families22.9.2026 15:00:00 CEST | Press release
Colgate-Palmolive builds on its legacy of oral health, publishing an impact evaluation, evolving its health education tools rooted in behavior change, and scaling its global health partnerships. Colgate-Palmolive, the worldwide leader in oral care, announced a strategic evolution in its flagship oral health education program, Colgate Bright Smiles, Bright Futures® (BSBF), reflecting the Company’s commitment to global public health. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260922129016/en/ Launched in 1991, the program has reached over two billion children and their families across more than 100 countries, demonstrating how private-sector commitment designed to support communities, can become a powerful force for public health, driving healthier behaviors and positive outcomes at scale. From health education curriculum and school programming to mobile dental vans and free oral health screenings, BSBF helps children and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom